Experimental drug XmAb27564 tested for skin conditions – trial halted early

NCT ID NCT06005792

Terminated Disease control Sponsor: Xencor, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental drug called XmAb27564 in 23 people with mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis. Participants received four doses of the drug or a placebo every two weeks. The main goal was to check safety and tolerability. The study was terminated, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XmAb27564
What this could lead to: If successful, this could point toward a new treatment option for plaque psoriasis and atopic dermatitis.
What could go wrong: This was a very early (Phase 1) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS PSORIASIS

Contacts and locations

Locations

Center for Clinical Studies, LTD. LLP

Webster, Texas, 77598, United States
Clinical Trials Research Institute

Thousand Oaks, California, 91320, United States
Driven Research

Coral Gables, Florida, 33134, United States
Innovaderm Research Inc.

Montreal, Quebec, H2X 2V1, Canada
J&S Studies, Inc

College Station, Texas, 77845, United States
San Marcus Research Clinic

Miami Lakes, Florida, 33104, United States
Unison Clinical Trials

Sherman Oaks, California, 91403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.